The primary objective of this study is to determine the AUC change in FGF23 within 24-72 hours caused by the SGLT2 inhibitor canagliflozin. We will also examine the effects of canagliflozin on various biochemical markers of bone metabolism (including phosphorus, PTH, various hydroxylated vitamin D derivatives, calcium, and markers of bone turnover) during the first 5 days of drug administration.